Latest Breaking News On - Biohaven labs - Page 1 : comparemela.com

Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University

Biohaven advances development of its extracellular target degrader platform technology (MoDEs™) for therapies across a variety of diseases including.

David spiegelJennifer porcelliMike beyerSpiegel labYale universityBiohaven ltdBiohaven therapeutics ltdPrnewswire biohaven ltdSam brown incProfessor david spiegel at yale universityExchange commissionProfessor david spiegelBiohaven labsProteolysis targeting chimerasProfessor spiegelSmall molecules

Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University

Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

David spiegelJennifer porcelliMike beyerSpiegel labYale universityBiohaven ltdBiohaven therapeutics ltdPrnewswire biohaven ltdSam brown incProfessor david spiegel at yale universityExchange commissionProfessor david spiegelBiohaven labsProteolysis targeting chimerasProfessor spiegelSmall molecules

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding - read this article along with other careers information, tips and advice on BioSpace

Ian readPaul bernsAdam koppelKnopp biosciencesIan pavordMichael bozikJorge bartolomeClive meanwellAreteia therapeutics incBiohaven pharmaceuticalsPartner at population health partnersBain capital life sciencesMedicines companyUniversity of oxfordPopulation health partnersPartner of population health partners

Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences

/PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") announced today that it has entered into a definitive.

United statesMichael bozikIrfan qureshiJen porcelliSteven dworetzkyKnopp biosciencesMike beyerBiohaven neuroinnovationBiohaven pharmaceuticalsExchange commission onCompany or biohavenWorld health organizationSam brown incExchange commissionCompany annual report on formBiohaven pharmaceutical holding company ltd

Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma

Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma - read this article along with other careers information, tips and advice on BioSpace

United statesDavid spiegelMike beyerCharlie conwayYale universitySam brown incExchange commissionBiohaven pharmaceutical holding company ltdCompany codesPeptidream incTokyo stock exchangeBiohaven pharma holding company ltdKleo pharmaceuticals incAmerican cancer societyBiohaven pharma holding companyMultiple myeloma